Rebecca Norris, MD
Family Medicine · Anderson, SCNPI 1932224177
Payments from drug & device makers
Across 300 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$646
- AstraZeneca$468
- Novo Nordisk$379
- Takeda Pharmaceuticals U.S.A., Inc.$320
- Abbott$314
- Novartis$313
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,418100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $646 |
| AstraZeneca | 28 | $468 |
| Novo Nordisk | 25 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $320 |
| Abbott | 17 | $314 |
| Novartis | 21 | $313 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $289 |
| Amgen | 18 | $260 |
| Boehringer Ingelheim | 12 | $156 |
| Bayer | 10 | $145 |
| Lilly USA, LLC | 7 | $103 |
| Eisai Inc. | 5 | $88 |
| Astellas Pharma US Inc | 5 | $82 |
| Boston Scientific | 4 | $77 |
| Medtronic | 3 | $61 |
| Ardelyx, Inc. | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 4 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Edwards Lifesciences | 2 | $42 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Amarin Pharma, Inc. | 3 | $41 |
| Lundbeck LLC | 2 | $40 |
| Merck | 3 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Pfizer | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| GSK | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Resmed Corp | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,432 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 738 | $211,685 |
| MounjaroTirzepatide | 109 | $113,610 |
| JardianceEmpagliflozin | 139 | $95,337 |
| OzempicSemaglutide | 83 | $92,388 |
| JanuviaSitagliptin Phosphate | 166 | $75,276 |
| FarxigaDapagliflozin Propanediol | 146 | $70,995 |
| TrulicityDulaglutide | 40 | $69,295 |
| KerendiaFinerenone | 45 | $57,538 |
| XareltoRivaroxaban | 85 | $51,608 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $39,676 |
| LinzessLinaclotide | 43 | $39,584 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $38,166 |
| Diclofenac Sodium | 298 | $36,606 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 130 | $31,300 |
| Repatha SureclickEvolocumab | 33 | $28,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $211,685738 claims |
| Lilly USA, LLCMounjaro, Trulicity | $103 | $182,905149 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $156 | $127,165164 claims |
| MerckJanuvia, Janumet | $37 | $114,952207 claims |
| Novo NordiskOzempic | $379 | $92,38883 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $468 | $91,908169 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $28 | $80,089126 claims |
| BayerKerendia | $145 | $57,53845 claims |
| Johnson & JohnsonXarelto | $21 | $51,60885 claims |
| AbbVieLinzess | $646 | $39,58443 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $27,04637 claims |
| NovartisEntresto | $313 | $18,19197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Anderson
- Erin CookseyAnderson$1.2M
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.